Canada Resets Clinical Trial Application Requirements

Clinical Trials Advisor
A A
Sponsors seeking to import drugs into Canada for trials must provide Health Canada with a “No Objection Letter” to facilitate shipment and demonstrate regulatory compliance, according to a November draft guidance on clinical trial applications (CTA).

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $25.00